Pengnam, S.; Opanasopit, P.; Rojanarata, T.; Yingyongnarongkul, B.-e.; Thongbamrer, C.; Plianwong, S.
Dual-Targeted Therapy in HER2-Overexpressing Breast Cancer with Trastuzumab and Novel Cholesterol-Based Nioplexes Silencing Mcl-1. Pharmaceutics 2023, 15, 2424.
https://doi.org/10.3390/pharmaceutics15102424
AMA Style
Pengnam S, Opanasopit P, Rojanarata T, Yingyongnarongkul B-e, Thongbamrer C, Plianwong S.
Dual-Targeted Therapy in HER2-Overexpressing Breast Cancer with Trastuzumab and Novel Cholesterol-Based Nioplexes Silencing Mcl-1. Pharmaceutics. 2023; 15(10):2424.
https://doi.org/10.3390/pharmaceutics15102424
Chicago/Turabian Style
Pengnam, Supusson, Praneet Opanasopit, Theerasak Rojanarata, Boon-ek Yingyongnarongkul, Chopaka Thongbamrer, and Samarwadee Plianwong.
2023. "Dual-Targeted Therapy in HER2-Overexpressing Breast Cancer with Trastuzumab and Novel Cholesterol-Based Nioplexes Silencing Mcl-1" Pharmaceutics 15, no. 10: 2424.
https://doi.org/10.3390/pharmaceutics15102424
APA Style
Pengnam, S., Opanasopit, P., Rojanarata, T., Yingyongnarongkul, B.-e., Thongbamrer, C., & Plianwong, S.
(2023). Dual-Targeted Therapy in HER2-Overexpressing Breast Cancer with Trastuzumab and Novel Cholesterol-Based Nioplexes Silencing Mcl-1. Pharmaceutics, 15(10), 2424.
https://doi.org/10.3390/pharmaceutics15102424
